Clinical trial · Interventional
Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer
Efficacy of Udenafil in Treatment of Erectile Dysfunction After Radical Resection for Sigmoid Colon and Rectal Cancer : a Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of Udenafil (Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea) in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. In this study, the efficacy of Udenafil will be evaluated in treatment for patient with chronic erectile dysfunction, which developed after radical resection for sigmoid and rectal cancer and continues 12 months after the surgery.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Erectile Dysfunction | — | UNRESOLVED | — |
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
| Sigmoid Colon Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Udenafil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- normal control group
- interventionNames
- Drug: Udenafil
- type
- EXPERIMENTAL
- label
- Udenafil
- description
- oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
- interventionNames
- Drug: Udenafil
Primary outcomes (1)
- measure
- Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)
- timeFrame
- at 4 weeks after enrollment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * • Male patients between 19-70 years old in good general health * Patient willing to treat postoperative erectile dysfunction and participate in the study * Patient who understands and accepts to sign the informed consent form * Patient who received radical resection for sigmoid colon and rectal cancer. : erectile dysfunction was developed following operation, not preoperatively * Scores of IIEF-5 measured at 12 months after surgery is 16 or less Exclusion Criteria: * • Documented problem of preoperative erectile dysfunction * Past history of myocardial infarction, cerebrovascular disease * Under administration of nitrate * Liver dysfunction (SGOT or SGPT 100 IU/L or more) * Kidney dysfunction (serum Creatinine 3mg/dl or more)
References
Publications (0)
Data not yet available